In adults with obesity, a 72-week treatment combining bimagrumab and semaglutide leads to an average weight loss of 24.2 kg and a 45.7% reduction in body fat while maintaining muscle mass, which is greater than the weight loss and fat reduction seen with semaglutide alone.
See the scientific wording
In adults with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities), a 72-week combination of intravenous bimagrumab (30 mg/kg every 12 weeks) and subcutaneous semaglutide (2.4 mg weekly) results in a mean weight loss of 24.2 kg and a 45.7% reduction in total body fat mass, while preserving lean mass, and produces greater weight loss and fat mass reduction than subcutaneous semaglutide (2.4 mg weekly) alone, which results in a mean weight loss of 16.5 kg and a 27.8% reduction in total body fat mass.
Very strong evidence
Randomized trialsOne high-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2026
In people with obesity, taking both drugs together for a year lost more fat and weight than taking just one drug, and kept more muscle intact. The study proved this combo works better than the single drug alone.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A drug blocks signals that tell fat cells to store energy and muscle cells to break down, while another drug tells the brain to feel full and eat less. This causes the body to burn fat for energy without losing muscle, leading to greater fat loss and more muscle retention than just reducing food intake alone.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In adults with obesity, a 72-week treatment combining bimagrumab and semaglutide leads to an average weight loss of 24.2 kg and a 45.7% reduction in body fat while maintaining muscle mass, which is greater than the weight loss and fat reduction seen with semaglutide alone.
Mechanism
1 studyOne drug tells fat cells to release stored energy and tells muscles not to break down, while another drug tells the brain to feel full and eat less. Together, they make the body burn fat for fuel without losing muscle, resulting in more fat loss and better muscle retention than eating less alone.
A drug blocks signals that tell fat cells to store energy and muscle cells to break down, while another drug tells the brain to feel full and eat less. This causes the body to burn fat for energy without losing muscle, leading to greater fat loss and more muscle retention than just reducing food intake alone.
A monoclonal antibody binds to activin type II receptors on adipose tissue and skeletal muscle cells, preventing myostatin and activin A from activating downstream signaling pathways.
Inhibition of the ActRII-ALK7 pathway in adipose tissue increases lipolysis and mobilization of stored lipids, enhancing fat breakdown.
Inhibition of the ActRII-ALK4 pathway in skeletal muscle increases protein synthesis and suppresses muscle protein degradation, preserving lean mass.
A GLP-1 receptor agonist crosses the blood-brain barrier and activates receptors in the hypothalamus and brainstem, suppressing hunger signals and increasing satiety.
Reduced caloric intake creates a sustained energy deficit, directing the body to utilize mobilized lipids as the primary fuel source.
The combined effect of enhanced lipid mobilization and preserved muscle mass results in a disproportionate loss of fat mass relative to lean mass.
Evidence from Studies
Supporting (1)
Community contributions welcome
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
In people with obesity, taking both drugs together for a year lost more fat and weight than taking just one drug, and kept more muscle intact. The study proved this combo works better than the single drug alone.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Combination Bimagrumab and Semaglutide vs Semaglutide Monotherapy for Weight Loss in Obesity
Population: Adults with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities); Intervention: 72-week combination of intravenous bimagrumab (30 mg/kg every 12 weeks) and subcutaneous semaglutide (2.4 mg weekly); Comparator: Subcutaneous semaglutide (2.4 mg weekly) alone; Outcomes: Mean change in body weight, total body fat mass percentage, lean mass; Duration: 72 weeks; Inclusion: Only randomized controlled trials with intention-to-treat analysis.
Double-Blind, Placebo-Controlled Trial of Bimagrumab and Semaglutide Combination vs Semaglutide Monotherapy in Obesity Over 72 Weeks
Population: Adults with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities); Intervention: Intravenous bimagrumab (30 mg/kg every 12 weeks) plus subcutaneous semaglutide (2.4 mg weekly); Comparator: Subcutaneous semaglutide (2.4 mg weekly) plus placebo infusion; Outcomes: Primary: mean change in body weight and total body fat mass; Secondary: lean mass preservation; Duration: 72 weeks; Design: Double-blind, parallel-group, multicenter, with stratification by baseline BMI and comorbidities.
Prospective Cohort Study of Weight Outcomes in Obese Adults Treated with Bimagrumab-Semaglutide Combination vs Semaglutide Monotherapy in Clinical Practice
Population: Adults with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities) receiving either combination therapy or semaglutide monotherapy in clinical practice; Intervention: Bimagrumab (30 mg/kg every 12 weeks IV) + semaglutide (2.4 mg weekly SC) vs semaglutide (2.4 mg weekly SC) alone; Comparator: Semaglutide monotherapy; Outcomes: Mean change in body weight, total body fat mass, lean mass; Duration: 72 weeks; Design: Prospective, matched cohort with baseline covariate adjustment for age, sex, comorbidities, and baseline BMI.
Case-Control Study of Extreme Weight Loss Responders vs Non-Responders to Bimagrumab-Semaglutide Combination Therapy in Obesity
Population: Adults with obesity treated for 72 weeks with either combination therapy or semaglutide alone; Cases: Individuals achieving >20 kg weight loss; Controls: Individuals achieving <10 kg weight loss; Comparator: Semaglutide monotherapy group; Outcomes: Baseline demographics, comorbidities, adherence, genetic markers; Duration: 72 weeks; Design: Retrospective, matched on age, sex, baseline BMI, and comorbidities.
Cross-Sectional Analysis of Body Composition Changes in Obese Adults After 72 Weeks of Bimagrumab-Semaglutide Combination Therapy
Population: Adults with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities) who completed 72 weeks of either combination therapy or semaglutide monotherapy; Intervention: Bimagrumab (30 mg/kg every 12 weeks IV) + semaglutide (2.4 mg weekly SC) vs semaglutide (2.4 mg weekly SC) alone; Outcomes: Mean body weight, total body fat mass percentage, lean mass at week 72; Duration: Single time point at week 72; Design: Non-longitudinal, one-time measurement with no follow-up.